company background image
CQCI

Cipla Quality Chemical IndustriesUGSE:CQCIL Stock Report

Market Cap

USh343.3b

7D

0%

1Y

-6.9%

Updated

16 Oct, 2021

Data

Company Financials
CQCIL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CQCIL Overview

Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines.

Price History & Performance

Summary of all time highs, changes and price drops for Cipla Quality Chemical Industries
Historical stock prices
Current Share PriceUSh94.00
52 Week HighUSh85.00
52 Week LowUSh105.00
Beta0.021
1 Month Change3.75%
3 Month Change-6.00%
1 Year Change-6.93%
3 Year Change-63.99%
5 Year Changen/a
Change since IPO-64.12%

Recent News & Updates

Shareholder Returns

CQCILUG PharmaceuticalsUG Market
7D0%2.3%0.6%
1Y-6.9%87.5%-0.09%

Return vs Industry: CQCIL underperformed the UG Pharmaceuticals industry which returned 87.5% over the past year.

Return vs Market: CQCIL underperformed the UG Market which returned -0.1% over the past year.

Price Volatility

Is CQCIL's price volatile compared to industry and market?
CQCIL volatility
CQCIL Beta0.021
Industry Beta0.56
Market Beta1

Stable Share Price: CQCIL is not significantly more volatile than the rest of UG stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: CQCIL's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005n/aNevin Bradfordhttps://www.ciplaqcil.co.ug

Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines. It offers Duovir-N; Lamivudine and Zidovudine; Efavir 60; Duomune; Nevirapine; Efavirenz, Lamivudine and Tenofovir; and Dolutegravir, Lamivudine and Tenofovir tablets for the treatment of HIV infection. The company also offers Lumartem/Lumet tablets for the treatment of malaria; and Texavir and Zentair for the treatment of of Hepatitis B infection.

Cipla Quality Chemical Industries Fundamentals Summary

How do Cipla Quality Chemical Industries's earnings and revenue compare to its market cap?
CQCIL fundamental statistics
Market CapUSh343.28b
Earnings (TTM)-USh10.54b
Revenue (TTM)USh284.54b

1.2x

P/S Ratio

-32.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CQCIL income statement (TTM)
RevenueUSh284.54b
Cost of RevenueUSh229.51b
Gross ProfitUSh55.03b
ExpensesUSh65.56b
Earnings-USh10.54b

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.89
Gross Margin19.34%
Net Profit Margin-3.70%
Debt/Equity Ratio25.5%

How did CQCIL perform over the long term?

See historical performance and comparison

Valuation

Is Cipla Quality Chemical Industries undervalued compared to its fair value and its price relative to the market?

2.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CQCIL (UGX94) is trading above our estimate of fair value (UGX44.71)

Significantly Below Fair Value: CQCIL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CQCIL is unprofitable, so we can't compare its PE Ratio to the African Pharmaceuticals industry average.

PE vs Market: CQCIL is unprofitable, so we can't compare its PE Ratio to the UG market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CQCIL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CQCIL is overvalued based on its PB Ratio (2.5x) compared to the XF Pharmaceuticals industry average (1.6x).


Future Growth

How is Cipla Quality Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cipla Quality Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Cipla Quality Chemical Industries performed over the past 5 years?

-63.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CQCIL is currently unprofitable.

Growing Profit Margin: CQCIL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CQCIL is unprofitable, and losses have increased over the past 5 years at a rate of 63.5% per year.

Accelerating Growth: Unable to compare CQCIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CQCIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).


Return on Equity

High ROE: CQCIL has a negative Return on Equity (-7.77%), as it is currently unprofitable.


Financial Health

How is Cipla Quality Chemical Industries's financial position?


Financial Position Analysis

Short Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its short term liabilities (UGX65.8B).

Long Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its long term liabilities (UGX24.7B).


Debt to Equity History and Analysis

Debt Level: CQCIL's debt to equity ratio (25.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CQCIL's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: CQCIL's debt is well covered by operating cash flow (79.5%).

Interest Coverage: CQCIL's interest payments on its debt are not well covered by EBIT (1.5x coverage).


Balance Sheet


Dividend

What is Cipla Quality Chemical Industries's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CQCIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CQCIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CQCIL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CQCIL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CQCIL is not paying a notable dividend for the UG market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CQCIL's dividend in 3 years as they are not forecast to pay a notable one for the UG market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.3yrs

Average management tenure


CEO

Nevin Bradford (64 yo)

7.92yrs

Tenure

Mr. Nevin J. Bradford has been the Chief Executive Officer and Executive Director of Cipla Quality Chemical Industries Limited since November 26, 2013. Mr. Bradford serves as an Executive Director and Head...


Leadership Team

Experienced Management: CQCIL's management team is seasoned and experienced (10.3 years average tenure).


Board Members

Experienced Board: CQCIL's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cipla Quality Chemical Industries Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Cipla Quality Chemical Industries Limited
  • Ticker: CQCIL
  • Exchange: UGSE
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: USh343.279b
  • Shares outstanding: 3.65b
  • Website: https://www.ciplaqcil.co.ug

Number of Employees


Location

  • Cipla Quality Chemical Industries Limited
  • Luzira Industrial Park
  • Plot 1-7, 1st Ring Road
  • Kampala
  • Uganda

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 16:00
End of Day Share Price2021/10/15 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.